Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males

Subjects in all dose groups will be randomized to the study group (J2H-1702 group) and the control group (Placebo group) in a 8:2 ratio. Adverse event (AE) collection, physical examination, vital signs, ECG, clinical laboratory tests, etc. will be performed to assess the safety and tolerability, and blood and urine sampling will be performed to assess the PK/PD characteristics. In addition, blood sampling for mass cytometry (multiple administration study) and baseline fibroscan will be performed for the exploratory evaluation.

Inclusion criteria

• A healthy male adult within the range of 19 to 45 years old
• BMI=18.0~27.0kg/m2 (Body mass index, BMI)
• A subject confirmed to be clinically healthy based on the medical history, physical examination, vitals signs, ECG, and appropriate clinical laboratory tests
• A subject who his spouse or partner agrees to use dual contraceptive methods and not to donate sperms
• A subject who has voluntarily agree to participate in the study

Exclusion criteria

• A subject who had or has the disease corresponding to clinically significant liver, etc.
• A subject with a history of gastrointestinal diseases or surgery
• A subject who has a history of clinically significant hypersensitivity to drugs containing 11β-HSD1 inhibitor
• A subject who has genetic problems such as galactose intolerance, Lap galactose intolerance, Lap lactase deficiencies, or glucose ∙galactose malabsorptivity, etc.
• One who has drug abuse and one who is positive response in urine drug screening tests
• A subject with abnormal vital signs at the screening visit
• A subject who has participated in another clinical trial or bioequivalence test
• A subject who donated whole blood or the ingredient, or received blood transfusion
• A subject who took drug metabolizing enzyme-inducing and inhibitory drugs
• A subject who consumes grapefruit/caffeine-containing food
• A subject who took any prescription drug or herbal medicine or took any Over The Counter Drug (OTC)
• High caffeine intaker, high alcohol intaker or excessive smoker
• A subject who cannot eat meals provided by the Clinical Trial institution.
• A subject who participated in this trial and were administered the investigational product.
• A subject who is positive for serum test
• A subject who the investigator deems inappropriate for this clinical trial.